Page 79 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

a
Figure 5. Followup frequencies of 16 unique AS cohorts (continued)
Year 1 2 3 4
AS cohort Month 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
√**
Kagawa PSA-test * √ √ √ √ √ √ √ √ √ √ √ √ √ √
Medical
University 118 DRE
Rebiopsy √
PSA-test √ √ √ √
Cleveland DRE
clinic 119
Rebiopsy √ √
PSA-test √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
PRIAS 120 DRE √ √ √ √ √ √
Rebiopsy √ √
PSA-test √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
PASS 121 DRE √ √ √ √ √ √
Rebiopsy √ √ √
Legends: √* = every 3-4 mo; √** = every 3-4 years; √*** = every 2 mo for 6 mo. Merged cell represents a range of followup
frequency; for example, a merged cell of 3 and 6 mo with a check mark in the middle of the merged cell means a followup
frequency of 3 to 6 mo.
MSKCC= Memorial Sloan-Kettering Cancer Center; UCHC= University of Connecticut Health Center; Four academic medical
centers=Cleveland Clinic Foundation, University of British Columbia and University of Miami; UCSF= University of California
at San Francisco; ProtecT= Prostate testing for cancer and Treatment Trial; PRIAS= Prostate cancer Research International
Active Surveillance; PASS= the Canary Prostate Active Surveillance Study)
a Cohorts of active surveillance in chronological order of starting enrollment year. Some cohorts had multiple publications
providing different pieces of information on followup protocol. In this case, only the earliest publication was used as the primary
citation of the cohort. See Table 2.5 for more detailed monitoring criteria in each cohort.

Table 4. Cohorts that used PSA (ng/mL) or PSA kinetics as part of followup protocol for AS
Cohorts or Centers PSA (ng/mL)
Baylor College of Medicine and MSKCC 106 PSA velocity >0.75 ng/mL/year
McGill University 107 Used but not specified
UCHC 108 Used but not specified
Four tertiary care academic medical canters 109 Used but not specified
University of Miami 110 PSA increase 25-50 %/year
UCSF 111 PSA velocity >0.75 ng/mL/yr; PSA DT <1 year
Royal Marsden Hospital 112 PSA DT<4 years; PSA velocity >1 ng/mL/year
Johns Hopkins 113 PSA kinetics were not used as part of triggers for
intervention
Toronto 114 PSA DT <2 years
MSKCC 115 >10
ProtecT (Prostate testing for cancer and Treatment Used but not specified
Trial) 116
Dana-Farber Cancer Institute 117 Used but not specified
Kagawa Medical University †118 PSA DT <2 years
Cleveland clinic 119 Used but not specified
PRIAS 120 PSA DT 0 to 3 years
PASS 121 PSA DT <3 years
PSA DT = PSA doubling time which is defined as the time PSA needs to double its start-value. PSA V = PSA velocity
(ng/mL/yr) which is the absolute increase of PSA values in one year.

40